Cristian Lupascu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristian Lupascu has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Ana Maria Trofin
Department of Surgery I, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 University Street, 700115 Iași, Romania
7 shared publications - Ramona Cadar
“Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
5 shared publications - Adi-Ionut Ciumanghel
Department of Anesthesia and Intensive Care, St. Spiridon Iasi County Emergency Clinical Hospital, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
4 shared publications - Alexandru Grigorie Nastase
Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
4 shared publications - Corina Lupascu Ursulescu
Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
4 shared publications - Eliza Isabela Bărbuță
“Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
4 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (19) , 3072
The Thoracic Footprint of Hepatocellular Carcinoma: A Mechanism-Based Imaging Narrative Review
A thoracic finding in a patient with hepatocellular carcinoma (HCC) may represent metastatic disease, vascular extension, treatment-related injury, or a complication of cirrhosis, and each carries different implications for staging and care. The mechanism behind the finding therefore matters as much as the finding itself. We searched the PubMed/MEDLINE database for articles published up to August 2026 and screened the reference lists of retrieved articles for additional relevant publications. The narrative review is organised into four domains: direct oncological involvement, vascular dissemination, treatment-related injury, and cirrhosis-associated mimics. Within each domain, computed tomography (CT) provides most of the chest assessment, while magnetic resonance imaging, echocardiography, and angiography address more specific anatomical or diagnostic questions. We next discuss common patterns of pulmonary metastasis alongside benign nodules common in transplant candidates, and the biological and small-lesion limitations of functional imaging. Thoracic findings gain meaning in the context of hepatic disease, vascular anatomy, and treatment history. Enhancement and alpha-fetoprotein have never been validated as noninvasive rule-out tests for pulmonary metastasis, so the choice between sampling and surveillance rests on multidisciplinary judgement of the costs of uncertainty, procedural feasibility, and evidence strength.
- 22 September 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (19) , 3072
Open AccessThe Thoracic Footprint of Hepatocellular Carcinoma: A Mechanism-Based Imaging Narrative Review
A thoracic finding in a patient with hepatocellular carcinoma (HCC) may represent metastatic disease, vascular extension, treatment-related injury, or a complication of cirrhosis, and each carries different implications for staging and care. The mechanism behind the finding therefore matters as much as the finding itself. We searched the PubMed/MEDLINE database for articles published up to August 2026 and screened the reference lists of retrieved articles for additional relevant publications. The narrative review is organised into four domains: direct oncological involvement, vascular dissemination, treatment-related injury, and cirrhosis-associated mimics. Within each domain, computed tomography (CT) provides most of the chest assessment, while magnetic resonance imaging, echocardiography, and angiography address more specific anatomical or diagnostic questions. We next discuss common patterns of pulmonary metastasis alongside benign nodules common in transplant candidates, and the biological and small-lesion limitations of functional imaging. Thoracic findings gain meaning in the context of hepatic disease, vascular anatomy, and treatment history. Enhancement and alpha-fetoprotein have never been validated as noninvasive rule-out tests for pulmonary metastasis, so the choice between sampling and surveillance rests on multidisciplinary judgement of the costs of uncertainty, procedural feasibility, and evidence strength.
- Open Access
- 20 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3144
Liver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies
Liver transplantation remains the definitive treatment for end-stage liver disease and acute liver failure, yet a critical and persistent shortage of donor organs results in thousands of preventable deaths annually worldwide. Xenotransplantation has emerged as a potential solution to this structural deficit. This narrative review traces the evolution of liver xenotransplantation, from early non-human primate trials in the 1960s through the application of CRISPR/Cas9-driven multi-gene editing platforms in contemporary porcine donors. The immunological barriers that drove the transition from primate to porcine donors are examined, including hyperacute rejection mediated by anti-α-Gal antibodies, coagulation dysregulation and xenograft thrombotic microangiopathy. The genetic engineering strategies underlying current triple-knockout, ten-gene-edited donor pigs are reviewed alongside the preclinical non-human primate evidence establishing biological feasibility. The three pig-to-human liver xenotransplantation studies published between 2025 and 2026 are then analyzed, encompassing heterotopic auxiliary transplantation in a brain-dead decedent, extracorporeal liver cross-circulation and the first auxiliary liver xenotransplantation in a living recipient with a documented 171-day survival. These cases collectively provide preliminary evidence supporting proof-of-concept for porcine hepatic bridging therapy, with current evidence supporting a role for xenogeneic liver support as a temporary bridge to recovery or allotransplantation rather than definitive organ replacement. Xenograft thrombotic microangiopathy is identified as the principal remaining biological barrier, and the substantial translational challenges, including reproducibility, scalability and regulatory readiness that must be resolved before broader clinical application can be considered.
- 20 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3144
Open AccessLiver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies
Liver transplantation remains the definitive treatment for end-stage liver disease and acute liver failure, yet a critical and persistent shortage of donor organs results in thousands of preventable deaths annually worldwide. Xenotransplantation has emerged as a potential solution to this structural deficit. This narrative review traces the evolution of liver xenotransplantation, from early non-human primate trials in the 1960s through the application of CRISPR/Cas9-driven multi-gene editing platforms in contemporary porcine donors. The immunological barriers that drove the transition from primate to porcine donors are examined, including hyperacute rejection mediated by anti-α-Gal antibodies, coagulation dysregulation and xenograft thrombotic microangiopathy. The genetic engineering strategies underlying current triple-knockout, ten-gene-edited donor pigs are reviewed alongside the preclinical non-human primate evidence establishing biological feasibility. The three pig-to-human liver xenotransplantation studies published between 2025 and 2026 are then analyzed, encompassing heterotopic auxiliary transplantation in a brain-dead decedent, extracorporeal liver cross-circulation and the first auxiliary liver xenotransplantation in a living recipient with a documented 171-day survival. These cases collectively provide preliminary evidence supporting proof-of-concept for porcine hepatic bridging therapy, with current evidence supporting a role for xenogeneic liver support as a temporary bridge to recovery or allotransplantation rather than definitive organ replacement. Xenograft thrombotic microangiopathy is identified as the principal remaining biological barrier, and the substantial translational challenges, including reproducibility, scalability and regulatory readiness that must be resolved before broader clinical application can be considered.
- Open Access
Early Bacterial Infections After Liver Transplantation: Risk Factors, Microbiological Spectrum, and Outcomes in an Eastern European Cohort
Early bacterial infections (EBI) remain a major cause of morbidity and mortality after liver transplantation (LT). This study aimed to characterize their incidence, microbiological spectrum, risk factors, and clinical impact in an Eastern European cohort. We retrospectively analyzed 64 adult LT recipients from a tertiary center, focusing on perioperative parameters, infection profiles, and postoperative outcomes. EBI, defined as infections occurring within 30 days after transplantation and diagnosed according to CDC/NHSN criteria, occurred in 48.4% of patients. Gram-negative bacilli predominated (73.7%), mainly Pseudomonas aeruginosa (34.2%) and Klebsiella pneumoniae (15.8%), while Clostridioides difficile (CDI) accounted for 18.4% of confirmed cases diagnosed by stool toxin assay. Infected patients had greater intraoperative blood loss (median 6500 mL vs. 5000 mL, p = 0.036) and required more transfusions. The higher infection rate in our cohort may also be related to longer surgical duration. All deaths within the first postoperative year occurred among infected recipients, yet overall 30-day (7.8%) and 1-year (14.1%) mortality rates remained within the range reported internationally, suggesting that timely diagnosis and adequate management limited the impact of infections on survival. These findings emphasize the importance of infection prevention, optimized transfusion and bleeding control, and tailored antibiotic prophylaxis based on local microbiological patterns after LT.
Open AccessEarly Bacterial Infections After Liver Transplantation: Risk Factors, Microbiological Spectrum, and Outcomes in an Eastern European Cohort
Early bacterial infections (EBI) remain a major cause of morbidity and mortality after liver transplantation (LT). This study aimed to characterize their incidence, microbiological spectrum, risk factors, and clinical impact in an Eastern European cohort. We retrospectively analyzed 64 adult LT recipients from a tertiary center, focusing on perioperative parameters, infection profiles, and postoperative outcomes. EBI, defined as infections occurring within 30 days after transplantation and diagnosed according to CDC/NHSN criteria, occurred in 48.4% of patients. Gram-negative bacilli predominated (73.7%), mainly Pseudomonas aeruginosa (34.2%) and Klebsiella pneumoniae (15.8%), while Clostridioides difficile (CDI) accounted for 18.4% of confirmed cases diagnosed by stool toxin assay. Infected patients had greater intraoperative blood loss (median 6500 mL vs. 5000 mL, p = 0.036) and required more transfusions. The higher infection rate in our cohort may also be related to longer surgical duration. All deaths within the first postoperative year occurred among infected recipients, yet overall 30-day (7.8%) and 1-year (14.1%) mortality rates remained within the range reported internationally, suggesting that timely diagnosis and adequate management limited the impact of infections on survival. These findings emphasize the importance of infection prevention, optimized transfusion and bleeding control, and tailored antibiotic prophylaxis based on local microbiological patterns after LT.
- Open Access
- 25 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (30) , e43575
Impact of massive hemorrhage on outcome in patients with orthotopic liver transplant: A retrospective unicenter study
Despite advancements in surgical and anesthetic techniques, significant bleeding remains a common challenge during orthotopic liver transplantation (OLT). The extensive nature of the surgical procedure, combined with the patient’s fragile coagulation profile, places individuals undergoing OLT at a high risk for massive hemorrhage (MH). Blood transfusions and hemostatic products are frequently required and can be life-saving. However, these resources are often limited, and their use may be associated with numerous complications. This study aimed to evaluate the impact of MH on the day of surgery on the outcomes of patients undergoing OLT from brain-dead donors at our institution. We conducted a retrospective single-center study including all adult patients who underwent OLT from brain-dead donors at the Emergency County Clinical Hospital “Saint Spiridon” in Iași. Preoperative circulating blood volume was calculated for each patient and compared with the estimated blood loss on the day of surgery. Patients who lost >1 circulating blood volume were classified as having experienced MH. The study population was divided into 2 groups: those with MH and those without. Outcomes were assessed based on 30-day and 1-year mortality, as well as medical and surgical complications. The study included 53 patients, with a median blood loss of 5500 mL (4650 mL). MH occurred in 26 patients (49.1%). Patients with a lower body mass index (24.3 vs 26.6, P = .028) and thrombocytopenia (55.5 vs 75 × 10³/µL, P = .04) were more likely to experience MH. Those with MH had higher rates of cardiovascular complications (38.5% vs 7.4%, P = .007), infectious complications (69.2% vs 37%, P = .009), and surgical reintervention (34.6% vs 11.1%, P = .04). Mortality rates at 30 days and 1 year did not significantly differ between patients with and without MH. MH adversely affects the outcomes of OLT patients, as evidenced by increased rates of cardiovascular and infectious complications and a higher likelihood of requiring surgical reintervention.
- 25 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (30) , e43575
Open AccessImpact of massive hemorrhage on outcome in patients with orthotopic liver transplant: A retrospective unicenter study
Despite advancements in surgical and anesthetic techniques, significant bleeding remains a common challenge during orthotopic liver transplantation (OLT). The extensive nature of the surgical procedure, combined with the patient’s fragile coagulation profile, places individuals undergoing OLT at a high risk for massive hemorrhage (MH). Blood transfusions and hemostatic products are frequently required and can be life-saving. However, these resources are often limited, and their use may be associated with numerous complications. This study aimed to evaluate the impact of MH on the day of surgery on the outcomes of patients undergoing OLT from brain-dead donors at our institution. We conducted a retrospective single-center study including all adult patients who underwent OLT from brain-dead donors at the Emergency County Clinical Hospital “Saint Spiridon” in Iași. Preoperative circulating blood volume was calculated for each patient and compared with the estimated blood loss on the day of surgery. Patients who lost >1 circulating blood volume were classified as having experienced MH. The study population was divided into 2 groups: those with MH and those without. Outcomes were assessed based on 30-day and 1-year mortality, as well as medical and surgical complications. The study included 53 patients, with a median blood loss of 5500 mL (4650 mL). MH occurred in 26 patients (49.1%). Patients with a lower body mass index (24.3 vs 26.6, P = .028) and thrombocytopenia (55.5 vs 75 × 10³/µL, P = .04) were more likely to experience MH. Those with MH had higher rates of cardiovascular complications (38.5% vs 7.4%, P = .007), infectious complications (69.2% vs 37%, P = .009), and surgical reintervention (34.6% vs 11.1%, P = .04). Mortality rates at 30 days and 1 year did not significantly differ between patients with and without MH. MH adversely affects the outcomes of OLT patients, as evidenced by increased rates of cardiovascular and infectious complications and a higher likelihood of requiring surgical reintervention.
- Open Access
- 9 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 4882
Clinical Impact of Viscoelastic Testing in Liver Transplantation: A Before-and-After Study of Transfusion Needs and Outcomes
Background/Objectives: Liver transplantation (LT) is often complicated by severe bleeding and coagulopathy. Viscoelastic testing (VET) offers real-time, bedside assessment of coagulation and may improve transfusion management compared to standard tests. This study evaluates the clinical impact of VET implementation during liver transplantation on bleeding, transfusion requirements, complications, and mortality in a single Eastern European tertiary transplant center. Methods: We conducted a single-center before-and-after study comparing patients undergoing LT before and after the implementation of VET. All procedures were performed by the same surgical and anesthetic team using a standardized protocol. Data were collected retrospectively for the Before VET group and prospectively for the After VET group. We compared transfusion requirements, bleeding, complications, and mortality. Results: A total of 59 patients were included, 22 in the After VET group and 37 in the Before VET group. VET implementation was associated with lower intraoperative blood loss (median 4000 mL vs. 6000 mL, p = 0.017) and reduced red blood cell (RBC) transfusion volume (670 mL vs. 1000 mL, p = 0.008). FFP (0.23 vs. 1.59 units, p = 0.007) and platelet use (0.68 vs. 1.81 units, p = 0.035) were also significantly lower in the VET group, while fibrinogen use was higher (3.00 g vs. 2.00 g, p = 0.036). No differences were observed in complication rates or mortality at 30 days and 1 year in this small before-and-after study. Conclusions: VET improved transfusion precision and individualized coagulation management during LT, leading to reduced use of blood products. These findings support the adoption of VET as a standard of care in LT protocols, as it may enhance patient safety, even though no differences in postoperative complications or mortality were observed.
- 9 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 4882
Open AccessClinical Impact of Viscoelastic Testing in Liver Transplantation: A Before-and-After Study of Transfusion Needs and Outcomes
Background/Objectives: Liver transplantation (LT) is often complicated by severe bleeding and coagulopathy. Viscoelastic testing (VET) offers real-time, bedside assessment of coagulation and may improve transfusion management compared to standard tests. This study evaluates the clinical impact of VET implementation during liver transplantation on bleeding, transfusion requirements, complications, and mortality in a single Eastern European tertiary transplant center. Methods: We conducted a single-center before-and-after study comparing patients undergoing LT before and after the implementation of VET. All procedures were performed by the same surgical and anesthetic team using a standardized protocol. Data were collected retrospectively for the Before VET group and prospectively for the After VET group. We compared transfusion requirements, bleeding, complications, and mortality. Results: A total of 59 patients were included, 22 in the After VET group and 37 in the Before VET group. VET implementation was associated with lower intraoperative blood loss (median 4000 mL vs. 6000 mL, p = 0.017) and reduced red blood cell (RBC) transfusion volume (670 mL vs. 1000 mL, p = 0.008). FFP (0.23 vs. 1.59 units, p = 0.007) and platelet use (0.68 vs. 1.81 units, p = 0.035) were also significantly lower in the VET group, while fibrinogen use was higher (3.00 g vs. 2.00 g, p = 0.036). No differences were observed in complication rates or mortality at 30 days and 1 year in this small before-and-after study. Conclusions: VET improved transfusion precision and individualized coagulation management during LT, leading to reduced use of blood products. These findings support the adoption of VET as a standard of care in LT protocols, as it may enhance patient safety, even though no differences in postoperative complications or mortality were observed.
- Open Access
- 8 April 2025
- Published by MDPI AG in Preprints.org
Clinical Impact of Viscoelastic Testing in Liver Transplantation: A Before-and-After Study of Transfusion Needs and Outcomes
Background/Objectives: Liver transplantation (LT) is often complicated by severe bleeding and coagulopathy. Viscoelastic testing (VET) offers real-time, bedside assessment of coagulation and may improve transfusion management compared to standard tests. This study evaluates the clinical impact of VET implementation during liver transplantation on bleeding, transfusion requirements, complications, and mortality. Methods: We conducted a single-center before-and-after study comparing patients undergoing LT before and after the implementation of VET. All procedures were performed by the same surgical and anesthetic team using a standardized protocol. Data were collected retrospectively for the Before VET group and prospectively for the After VET group. We compared transfusion requirements, bleeding, complications, and mortality. Results: A total of 59 patients were included, 22 in the After VET group and 37 in the Before VET group. VET implementation was associated with lower intraoperative blood loss (median 4000 mL vs. 6000 mL, p = 0.017) and reduced allogeneic blood transfusion (670 mL vs. 1000 mL, p = 0.008). FFP (0.23 vs. 1.59 units, p = 0.007) and platelet use (0.68 vs. 1.81 units, p = 0.035) were also significantly lower in the VET group, while fibrinogen use was higher (3.00 g vs. 2.00 g, p = 0.036). No differences were observed in complication rates or mortality at 30 days and 1 year. Conclusions: VET significantly improved transfusion precision and individualized coagulation management during LT, leading to reduced use of blood products. These findings support the adoption of VET as a standard of care in LT protocols, as it may enhance patient safety, even though no differences in postoperative complications or mortality were observed.
- 8 April 2025
- Published by MDPI AG in Preprints.org
Open AccessClinical Impact of Viscoelastic Testing in Liver Transplantation: A Before-and-After Study of Transfusion Needs and Outcomes
Background/Objectives: Liver transplantation (LT) is often complicated by severe bleeding and coagulopathy. Viscoelastic testing (VET) offers real-time, bedside assessment of coagulation and may improve transfusion management compared to standard tests. This study evaluates the clinical impact of VET implementation during liver transplantation on bleeding, transfusion requirements, complications, and mortality. Methods: We conducted a single-center before-and-after study comparing patients undergoing LT before and after the implementation of VET. All procedures were performed by the same surgical and anesthetic team using a standardized protocol. Data were collected retrospectively for the Before VET group and prospectively for the After VET group. We compared transfusion requirements, bleeding, complications, and mortality. Results: A total of 59 patients were included, 22 in the After VET group and 37 in the Before VET group. VET implementation was associated with lower intraoperative blood loss (median 4000 mL vs. 6000 mL, p = 0.017) and reduced allogeneic blood transfusion (670 mL vs. 1000 mL, p = 0.008). FFP (0.23 vs. 1.59 units, p = 0.007) and platelet use (0.68 vs. 1.81 units, p = 0.035) were also significantly lower in the VET group, while fibrinogen use was higher (3.00 g vs. 2.00 g, p = 0.036). No differences were observed in complication rates or mortality at 30 days and 1 year. Conclusions: VET significantly improved transfusion precision and individualized coagulation management during LT, leading to reduced use of blood products. These findings support the adoption of VET as a standard of care in LT protocols, as it may enhance patient safety, even though no differences in postoperative complications or mortality were observed.
- 1 March 2023
- Published by Edizioni Minerva Medica in Chirurgia
- Vol. 36 (1) , 5-9
Prognostic factors for outcome of liver transplantion hepatitis C cirrhosis
Article: Prognostic factors for outcome of liver transplantion hepatitis C cirrhosis - Chirurgia 2023 February;36(1):5-9 - Minerva Medica - Journals
- 1 March 2023
- Published by Edizioni Minerva Medica in Chirurgia
- Vol. 36 (1) , 5-9
Prognostic factors for outcome of liver transplantion hepatitis C cirrhosis
Article: Prognostic factors for outcome of liver transplantion hepatitis C cirrhosis - Chirurgia 2023 February;36(1):5-9 - Minerva Medica - Journals
- Open Access
- 20 April 2021
- Published by Jurnalul de Chirurgie (Journal of Surgery) in Jurnalul de Chirurgie
- Vol. 17 (1) , 20-36
Peritoneal hydatic cysts: a series of cases and the review of literature
Primary peritoneal hydatidosis is an extremely rare ( 2% of all intra-abdominal hydatid disease). Peritoneal hydatid disease is secondary to liver or splenic involvement following spontaneous rupture or accidental spillage during surgery. Methods: We made a retrospective study based on the analysis of the database of the I Surgery Clinic of the University Emergency Hospital „St. Spiridon ”from Iași, with peritoneal hydatid cyst, including all the data from the medical files. Between 1991 and 2021 a total of 18 patients were operated for primary (3) or secondary peritoneal cysts (15). During the same period, 1002 cases of hydatid cyst with various locations were treated in the Iasi Surgery Clinic: 805 abdominal (714 hepatic, 43 splenic, and 18 peritoneal) and 197 extra abdominal (thoracic, cervical, muscular, retroperitoneal, etc.). The incidence of hydatid diseases has decreased over time from 35 cases per year to 18 cases per year. In the year of the COVID pandemic (2020) the incidence decreased to 10 cases per year.Most of the patients with peritoneal hydatidosis were asymptomatic or had atypical symptoms. The diagnosis was based on the preoperative history, rupture of the cysts, serology, ultrasound and computer tomography. Open surgery was the procedure of choice (16 cases) with conservative (13 cysts) and radical (3 cysts) methods. The laparoscopic approach was performed in 2 cases of primary peritoneal hydatid cysts. Results: The outcome of surgery was good without postoperative mortality or severe morbidity and the recurrence rate was 22.2%. Conclusions: Peritoneal hydatidosis is a rare disease; it is important to prevent the disease. Clinical signs and symptoms are nonspecific for a long time.We suspect this diagnosis in the case of abdominal cystic tumors especially in endemic regions. The diagnosis is made based on the history of operated hydatid disease, clinical signs, imaging and immunological tests. Total surgical excision of hydatid cysts or partial perichystectomy after evacuation of the inactivated cyst is the chosen treatment. Proper perioperative medical treatment prevents recurrence. Long-term follow-up is necessary to detect and treat any recurrence.
- 20 April 2021
- Published by Jurnalul de Chirurgie (Journal of Surgery) in Jurnalul de Chirurgie
- Vol. 17 (1) , 20-36
Open AccessPeritoneal hydatic cysts: a series of cases and the review of literature
Primary peritoneal hydatidosis is an extremely rare ( 2% of all intra-abdominal hydatid disease). Peritoneal hydatid disease is secondary to liver or splenic involvement following spontaneous rupture or accidental spillage during surgery. Methods: We made a retrospective study based on the analysis of the database of the I Surgery Clinic of the University Emergency Hospital „St. Spiridon ”from Iași, with peritoneal hydatid cyst, including all the data from the medical files. Between 1991 and 2021 a total of 18 patients were operated for primary (3) or secondary peritoneal cysts (15). During the same period, 1002 cases of hydatid cyst with various locations were treated in the Iasi Surgery Clinic: 805 abdominal (714 hepatic, 43 splenic, and 18 peritoneal) and 197 extra abdominal (thoracic, cervical, muscular, retroperitoneal, etc.). The incidence of hydatid diseases has decreased over time from 35 cases per year to 18 cases per year. In the year of the COVID pandemic (2020) the incidence decreased to 10 cases per year.Most of the patients with peritoneal hydatidosis were asymptomatic or had atypical symptoms. The diagnosis was based on the preoperative history, rupture of the cysts, serology, ultrasound and computer tomography. Open surgery was the procedure of choice (16 cases) with conservative (13 cysts) and radical (3 cysts) methods. The laparoscopic approach was performed in 2 cases of primary peritoneal hydatid cysts. Results: The outcome of surgery was good without postoperative mortality or severe morbidity and the recurrence rate was 22.2%. Conclusions: Peritoneal hydatidosis is a rare disease; it is important to prevent the disease. Clinical signs and symptoms are nonspecific for a long time.We suspect this diagnosis in the case of abdominal cystic tumors especially in endemic regions. The diagnosis is made based on the history of operated hydatid disease, clinical signs, imaging and immunological tests. Total surgical excision of hydatid cysts or partial perichystectomy after evacuation of the inactivated cyst is the chosen treatment. Proper perioperative medical treatment prevents recurrence. Long-term follow-up is necessary to detect and treat any recurrence.
- Open Access
- 1 January 2021
- Published by Celsius Publishing House in Chirurgia
- Vol. 116 (4) , 473-479
The Use of Mucolytic Agent in Percutaneous Drainage of Liver Abscess: A Case-Series Analysis
Background: Liver abscess is a scarce but potentially fatal suppurative process. There is a general tendency for minimally invasive treatment, such as broad-spectrum antibiotherapy and percutaneous drainage. Multiloculated, multiple or incompletely liquefied abscesses often limit the efficacy of percutaneous drainage. This study aims to assess the effectiveness of percutaneous drainage and intracavitary instillation of a mucolytic agent for liver abscesses. Material and method: From our department database, we have identified patients with liver abscess admitted during the period 2015 - 2020, treated by ultrasound-guided percutaneous drainage and intracavitary instillation of mucolytic agent. Data regarding imaging appearance, drainage technique, inflammatory markers and clinical course were assessed. Results: Twenty-one patients with multiloculated liver abscesses, sized 8 to 17 cm, were percutaneously drained, with local anaesthesia, under ultrasound guidance. The bacteriological exam of the aspirate showed bacterial infection in 19 cases, mostly Klebsiella pneumoniae, and 2 fungal infections. Acetylcysteine in dilution 1: 1 with saline was instilled daily on the 12F or 14 F drainage catheter. Clinical and radiological resolution was achieved within 14 to 29 days. Two cases required supplementary drainage of a non-communicating residual cavity. There were no complications, periprocedural deaths or relapse at 3 months follow-up. Conclusions: Percutaneous drainage is effective even in the management of multiloculated liver abscesses, facilitated by the use of intracavitary mucolytic agent.
- 1 January 2021
- Published by Celsius Publishing House in Chirurgia
- Vol. 116 (4) , 473-479
Open AccessThe Use of Mucolytic Agent in Percutaneous Drainage of Liver Abscess: A Case-Series Analysis
Background: Liver abscess is a scarce but potentially fatal suppurative process. There is a general tendency for minimally invasive treatment, such as broad-spectrum antibiotherapy and percutaneous drainage. Multiloculated, multiple or incompletely liquefied abscesses often limit the efficacy of percutaneous drainage. This study aims to assess the effectiveness of percutaneous drainage and intracavitary instillation of a mucolytic agent for liver abscesses. Material and method: From our department database, we have identified patients with liver abscess admitted during the period 2015 - 2020, treated by ultrasound-guided percutaneous drainage and intracavitary instillation of mucolytic agent. Data regarding imaging appearance, drainage technique, inflammatory markers and clinical course were assessed. Results: Twenty-one patients with multiloculated liver abscesses, sized 8 to 17 cm, were percutaneously drained, with local anaesthesia, under ultrasound guidance. The bacteriological exam of the aspirate showed bacterial infection in 19 cases, mostly Klebsiella pneumoniae, and 2 fungal infections. Acetylcysteine in dilution 1: 1 with saline was instilled daily on the 12F or 14 F drainage catheter. Clinical and radiological resolution was achieved within 14 to 29 days. Two cases required supplementary drainage of a non-communicating residual cavity. There were no complications, periprocedural deaths or relapse at 3 months follow-up. Conclusions: Percutaneous drainage is effective even in the management of multiloculated liver abscesses, facilitated by the use of intracavitary mucolytic agent.
- Open Access
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1) , 3124304
Poly(vinyl alcohol boric acid)‐Diclofenac Sodium Salt Drug Delivery Systems: Experimental and Theoretical Studies
The main aim of the paper was to simulate the drug release by a multifractal theoretical model, as a valuable method to assess the drug release mechanism. To do this, drug delivery films were prepared by mixing poly(vinyl alcohol boric acid) (PVAB) and diclofenac (DCF) sodium salt drug in different mass ratios from 90/10 to 70/30, in order to obtain drug delivery systems with different releasing rates. The different drug content of the three systems was confirmed by energy‐dispersive spectroscopy (EDAX) analysis, and the encapsulation particularities were investigated by scanning electron microscopy (SEM), atomic force microscopy (AFM), and polarized optical microscopy (POM) techniques. The ability of the PVAB matrix to anchor the DCF was assessed by Fourier transform infrared (FTIR) spectroscopy. The in vitro release of the diclofenac sodium salt from the formulations was investigated in biomimetic conditions (pH = 7.4 and 37°C) by UV‐Vis spectroscopy, measuring the absorbance of the drug at 275 nm and fitting the results on a previously drawn calibration curve. An estimation of the drug release kinetics was performed by fitting three traditional mathematical models on experimental release data. Further, the drug delivery was simulated by the fractal theory of motion, in which the release dynamics of the polymer‐drug complex system is described through various Riccati‐type “regimes.” To explain such dynamics involved multifractal self‐modulation in the form of period doubling, quasiperiodicity, intermittency, etc., as well as multifractal self‐modulation of network type. Standard release dynamics were explained by multifractal behaviors of temporary kink type. The good correlation between the traditional mathematical models and the new proposed theoretical model demonstrated the validity of the multifractal model for the investigation of the drug release.
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1) , 3124304
Open AccessPoly(vinyl alcohol boric acid)‐Diclofenac Sodium Salt Drug Delivery Systems: Experimental and Theoretical Studies
The main aim of the paper was to simulate the drug release by a multifractal theoretical model, as a valuable method to assess the drug release mechanism. To do this, drug delivery films were prepared by mixing poly(vinyl alcohol boric acid) (PVAB) and diclofenac (DCF) sodium salt drug in different mass ratios from 90/10 to 70/30, in order to obtain drug delivery systems with different releasing rates. The different drug content of the three systems was confirmed by energy‐dispersive spectroscopy (EDAX) analysis, and the encapsulation particularities were investigated by scanning electron microscopy (SEM), atomic force microscopy (AFM), and polarized optical microscopy (POM) techniques. The ability of the PVAB matrix to anchor the DCF was assessed by Fourier transform infrared (FTIR) spectroscopy. The in vitro release of the diclofenac sodium salt from the formulations was investigated in biomimetic conditions (pH = 7.4 and 37°C) by UV‐Vis spectroscopy, measuring the absorbance of the drug at 275 nm and fitting the results on a previously drawn calibration curve. An estimation of the drug release kinetics was performed by fitting three traditional mathematical models on experimental release data. Further, the drug delivery was simulated by the fractal theory of motion, in which the release dynamics of the polymer‐drug complex system is described through various Riccati‐type “regimes.” To explain such dynamics involved multifractal self‐modulation in the form of period doubling, quasiperiodicity, intermittency, etc., as well as multifractal self‐modulation of network type. Standard release dynamics were explained by multifractal behaviors of temporary kink type. The good correlation between the traditional mathematical models and the new proposed theoretical model demonstrated the validity of the multifractal model for the investigation of the drug release.